Portfolio – 82VS

Portfolio

A diverse team building with exceptional scientists

Launching new companies and supporting strategic investments

Collectively the companies built and supported by 82VS are pursuing next generation innovative treatments for oncology, neurodegeneration, autoimmune disease, hereditary blindness and more…

Aakha Biologics discovers and develops biologics to create life-saving therapies for cancer patients.

Visit Site →

Indications:

Oncology

Modalities:

Antibody

Aldebaran Therapeutics is advancing medicines for genetic ocular disease.

Visit Site →

Indications:

Ophthalmology

Modalities:

Genetic Medicines

Broadwing Bio is developing antibody therapies for the leading causes of adult vision loss.

Visit Site →

Indications:

Ophthalmology

Modalities:

Antibody

Cantai is developing bispecific antibodies that can aid millions of patients suffering from immune-mediated and autoimmune diseases.

Indications:

Autoimmune

Modalities:

Bispecific

Voro is developing tumor-activated antibodies to unleash the cancer immunotherapy of myeloid cells.

Visit Site →

Indications:

Oncology

Modalities:

Bispecific

Synkentro is developing agonists of immunosuppressive receptors for treatment of autoimmune disease.

Indications:

Autoimmune

Modalities:

Bispecific

Ypsilon Therapeutics is developing T cell receptor mimics (TCRm) against validated tumor antigens for the treatment of cancers.

Visit Site →

Indications:

Oncology

Modalities:

TCRm

NewCo Launching Soon

Indications:

Obesity

Modalities:

Antibody

NewCo Launching Soon

Indications:

Autoimmune

Modalities:

Bispecific

NewCo Launching Soon

Indications:

Immunology

Modalities:

Bispecific

Aldebaran Therapeutics is advancing medicines for genetic ocular disease.

Indications:

Ophthalmology

Modalities:

Genetic Medicines

Broadwing Bio is developing antibody therapies for the leading causes of adult vision loss.

Indications:

Ophthalmology

Modalities:

Antibody